Mankind Pharma Ltd share price logo

Mankind Pharma Ltd Share Price

(MANKIND)

Large Cap

Healthcare Sector

₹2350.5▲1.58%

as on 04:01PM, 11 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

🔔 Integration Alert

Mankind Pharma's board approved a committee to evaluate integration structures for Bharat Serums and Vaccines (BSV), with a decision expected in coming months.

Mankind Pharma Ltd Performance

  • Day's Low

    Day's High

    ₹2,316
    Day's Price Range
    ₹2,384.95

  • 52 Week's Low

    52 Week's High

    ₹1,901.05
    52-Week Price Range
    ₹3,054.8
1 Month Return+ 8.27 %
3 Month Return-11.83 %
1 Year Return+ 3.67 %
Previous Close₹2,313.95
Open₹2,369.00
Volume2.99L
Upper Circuit₹2,776.70
Lower Circuit₹1,851.20
Market Cap₹96,976.58Cr

Mankind Pharma Ltd Fundamentals

P/E Ratio

19.29

PEG Ratio

1.23

Market Cap

₹87,426.64 Cr

P/B Ratio

6.43

EPS

38.31

Dividend Yield

0.3

Sector

Pharmaceuticals

ROE

23.45

Mankind Pharma Ltd Analyst Rating

based on 17 analysts

BUY

76.47%

Buy

11.76%

Hold

11.76%

Sell

Based on 17 analysts offering long term price targets for Mankind Pharma Ltd. An average target of ₹2789.59

Source: S&P Global Market Intelligence

Mankind Pharma Ltd Share analysis

Mankind Pharma Ltd price forecast by 17 analysts

Upside of18.68%

High

₹3300

Target

₹2789.59

Low

₹2150

Mankind Pharma Ltd target price ₹2789.59, a slight upside of 18.68% compared to current price of ₹2350.5. According to 17 analysts rating.

Source: S&P Global Market Intelligence

Key events for Mankind Pharma Ltd

  • Mankind Pharma Plans Integration of Bharat Serums - 14 Apr, 2025

    Mankind Pharma's board has approved the formation of a committee to explore structural integration options for Bharat Serums and Vaccines (BSV), following last year's acquisition deal.

  • NCLT Approves Amalgamation for Mankind Pharma Subsidiary - 01 Apr, 2025

    The National Company Law Tribunal approved the amalgamation of BSV Pharma, a subsidiary of Mankind Pharma, with Bharat Serums and Vaccines, effective May 9, 2022.

  • Mankind Pharma Completes Subsidiary Amalgamation Successfully - 29 Mar, 2025

    Mankind Pharma has successfully completed the amalgamation of three subsidiaries—Shree Jee Laboratory, JPR Labs, and Jaspack Industries—effective March 29, 2025, following NCLT approval. The merger aims to streamline operations and enhance synergy, with the authorized share capital adjusted to Rs 421.51 crore.

  • Mankind Pharma Faces ₹183 Crore Tax Demand - 28 Mar, 2025

    Mankind Pharma has received a ₹183 crore tax demand from the Income Tax Department for AY 2014-15 to 2017-18. The company plans to appeal, asserting the demand is unjustified and will not materially impact its operations.

  • Mankind Pharma Shares Surge Amid FTSE Rebalancing - 21 Mar, 2025

    Mankind Pharma shares experienced a significant rise as the FTSE's March semi-annual rebalancing came into effect, contributing to increased trading volumes.

Insights on Mankind Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 6.99% to 7.83% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 2.53K Cr → 3.31K Cr (in ₹), with an average increase of 8.4% per quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 12.37% to 13.34% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 2.86% to 2.90% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, MANKIND stock has moved down by -1.4%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 74.87% to 72.71% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 653.47 Cr → 380.23 Cr (in ₹), with an average decrease of 41.8% per quarter

Mankind Pharma Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹2,606.95Cr (-)₹2,441.10Cr (↓6.36%)₹2,893.42Cr (↑18.53%)₹3,076.51Cr (↑6.33%)₹3,230.00Cr (↑4.99%)
Net Income₹459.81Cr (-)₹476.59Cr (↑3.65%)₹543.07Cr (↑13.95%)₹658.88Cr (↑21.33%)₹384.52Cr (↓41.64%)
Net Profit Margin17.64% (-)19.52% (↑10.66%)18.77% (↓3.84%)21.42% (↑14.12%)11.90% (↓44.44%)
Value in ₹ crore
Details2021202220232024
Total Assets₹5,989.77Cr (-)₹9,103.97Cr (↑51.99%)₹9,634.50Cr (↑5.83%)₹11,765.16Cr (↑22.11%)
Total Liabilities₹1,255.50Cr (-)₹2,563.52Cr (↑104.18%)₹1,850.59Cr (↓27.81%)₹2,141.35Cr (↑15.71%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹959.61Cr (-)₹983.38Cr (↑2.48%)₹821.44Cr (↓16.47%)₹1,798.99Cr (↑119.00%)₹1,982.97Cr (↑10.23%)

Mankind Pharma Ltd Index Inclusions

S&P BSE Largecap

₹8,785.27

1.83 (▲158.27%)

Nifty 500

₹20,752.85

1.95 (▲396.1%)

Nifty MidSmallcap 400

₹17,243.80

2.29 (▲385.9%)

S&P BSE 100 LargeCap TMC

₹8,426.61

1.81 (▲149.88%)

Nifty Healthcare

₹13,326.65

1.53 (▲200.35%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

BSE 500

₹32,666.11

1.94 (▲621.53%)

NIFTY PHARMA

₹20,461.90

2.43 (▲485.6%)

Nifty LargeMidcap 250

₹14,412.95

1.84 (▲260.7%)

Nifty Midcap 100

₹50,501.50

1.85 (▲919.45%)

Nifty Midcap 150

₹18,614.15

1.87 (▲341.4%)

BSE Healthcare

₹40,398.88

2.11 (▲836.36%)

BSE 200

₹10,303.75

1.83 (▲184.73%)

Nifty 200

₹12,623.85

1.82 (▲225.9%)

S&P BSE 250 LargeMidCap

₹9,748.15

1.84 (▲175.99%)

Mankind Pharma Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
72.71%
-2.89
Foreign Institutions
13.34%
7.85
Mutual Funds
7.83%
12.07
Retail Investors
2.9%
1.35
Others
3.23%
10.67

Mankind Pharma Ltd Key Indicators

Details20202021202220232024
Return On Equity %28.5325.8624.6517.4320.95
Details2021202220232024
Return On Assets %21.1315.7513.316.26
Details2024
Book Value Per Share (₹)233.73
Details2024
Earning Per Share (₹)48.47

Mankind Pharma Ltd Valuation

Mankind Pharma Ltd in the last 5 years

  • Overview

  • Trends

Lowest (40.63x)

August 5, 2024

Today (46.17x)

April 11, 2025

Industry (50.30x)

April 11, 2025

Highest (57.70x)

January 3, 2025

LowHigh

Mankind Pharma Ltd Earnings and Dividends

  • Mankind Pharma Ltd Earnings Results

    Mankind Pharma Ltd’s net profit fell -16.2% since last year same period to ₹380.23Cr in the Q3 2024-2025. On a quarterly growth basis, Mankind Pharma Ltd has generated -41.81% fall in its net profits since last 3-months.

    Read More about Earnings Results

Mankind Pharma Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Mankind Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Mankind Pharma Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
HOLD₹87,426.64 Cr31.24%0.64₹3,854 Cr₹19,547 Cr
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd
HOLD₹92,582.82 Cr9.14%0.52₹5,577 Cr₹28,011 Cr
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd
BUY₹1,05,894.82 Cr34.5%0.67₹1,656 Cr₹10,727 Cr
Divis Laboratories Ltd
Divis Laboratories Ltd
HOLD₹1,48,378.35 Cr26.67%0.50₹1,600 Cr₹7,845 Cr
Cipla Ltd
Cipla Ltd
BUY₹1,18,158.42 Cr29.4%0.50₹4,155 Cr₹25,774 Cr
See all

About Mankind Pharma Ltd

Mankind Pharma Ltd. was established in 1991 as a Private Limited Company. In 2005 it was converted to a Public Limited Company and the name changed to Mankind Pharma Limited. The Company is engaged in the development, manufacturing and marketing of a range of pharmaceuticals and consumer healthcare products, and is active in acute and chronic therapeutic areas such as anti-infectives, cardiovascular and gastrointestinal treatments, antidiabetic and neuro/CNS medicines, vitamins, minerals and nutrients. In 2004, they entered the chronic pharmaceutical segment, and have added further products over the years, including ophthalmic products, consumer healthcare products, animal healthcare products and specialty therapeutic divisions. They operate 23 manufacturing facilities across India and had 2181 manufacturing personnel as of March 31, 2021. It is now planning to raise capital through the public offering of 40058844 equity shares, with a total installed capacity of 40.77 billion units across a range of products.

Revenue: ₹3,230.00Cr as on December 2024 (Q4 24)
Net Profit: ₹384.52Cr as on December 2024 (Q4 24)
Listing date: 09 May, 2023
Chairperson Name: RAMESH CHAND JUNEJA
OrganisationMankind Pharma Ltd
HeadquartersNew Delhi
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Mankind Pharma Ltd

What is Mankind Pharma Ltd price today?

Mankind Pharma Ltd share price today stands at ₹2350.5, Open: ₹2369, Previous Close: ₹2313.95, High: ₹2384.95, Low: ₹2316, 52 Week High: ₹3054.8, 52 Week Low: ₹1901.05.

How to Buy Mankind Pharma Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Mankind Pharma Ltd shares

What are today's traded volumes of Mankind Pharma Ltd?

Today's traded volume of Mankind Pharma Ltd(MANKIND) is 2.99L.

What is today's market capitalisation of Mankind Pharma Ltd?

Today's market capitalisation of Mankind Pharma Ltd(MANKIND) is ₹96976.58Cr.

What is the 52 Week High and Low Range of Mankind Pharma Ltd?

Mankind Pharma Ltd (MANKIND)
Price
52 Week High
₹3054.8
52 Week Low
₹1901.05

How much percentage Mankind Pharma Ltd is down from its 52 Week High?

Mankind Pharma Ltd (MANKIND) share price is ₹2350.5. It is down -23.06% from its 52 Week High price of ₹3054.8

How much percentage Mankind Pharma Ltd is up from its 52 Week low?

Mankind Pharma Ltd (MANKIND) share price is ₹2350.5. It is up 23.64% from its 52 Week Low price of ₹1901.05